The chronic kidney disease epidemiology collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?

European Journal of Haematology

Volumn 91, Issue 4, 2013, Pages 347-355

  Terpos, Evangelos ^a   Christoulas, Dimitrios ^b   Kastritis, Efstathios ^a   Katodritou, Eirini ^c   Pouli, Anastasia ^d   Michalis, Eurydiki ^e   Papassotiriou, Ioannis ^f   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^c THEAGENIO CANCER HOSPITAL   (Greece)

^d Aghios Savas Cancer Center   (Greece)

^e G GENNIMATAS GENERAL HOSPITAL   (Greece)

^f AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Chronic Kidney Disease Epidemiology Collaboration; Cystatin C; Estimated glomerular filtration rate; Modification of Diet in Renal Disease formula; Multiple myeloma; Renal dysfunction

Indexed keywords

CYSTATIN C; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; ENZYME BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

CHRONIC KIDNEY DISEASE EPIDEMIOLOGY COLLABORATION; CYSTATIN C; ESTIMATED GLOMERULAR FILTRATION RATE; MODIFICATION OF DIET IN RENAL DISEASE FORMULA; MULTIPLE MYELOMA; RENAL DYSFUNCTION;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CREATININE; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84884814364     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12164     Document Type: Article

References (26)

1. Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008;22:1485-93.
2. Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, Michali E, Economopoulos T, Zervas K, Dimopoulos MA. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 2007;48:337-41.
3. Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: who are we missing? Nephrol Dial Transplant 2001;16:1042-6.
4. Baxmann AC, Ahmed MS, Marques NC, Menon VB, Pereira AB, Kirsztajn GM, Heilberg IP. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol 2008;3:348-54.
5. Prigent A. Monitoring renal function and limitations of renal function tests. Semin Nucl Med 2008;38:32-46.
6. Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010;28:4976-84.
7. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 2005;67:2089-100.
8. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002;40:221-6.
9. O'Riordan SE, Webb MC, Stowe HJ, Simpson DE, Kandarpa M, Coakley AJ, Newman DJ, Saunders JA, Lamb EJ. Cystatin C improves the detection of mild renal dysfunction in older patients. Ann Clin Biochem 2003;40:648-55.
10. Madero M, Sarnak MJ, Stevens LA. Serum cystatin C as a marker of glomerular filtration rate. Curr Opin Nephrol Hypertens 2006;15:610-6.
11. Terpos E, Katodritou E, Tsiftsakis E, et al. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica 2009;94:372-9.
12. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20-9.
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
14. Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 1999;13:79-90.
15. Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martínez-Brú C, Grubb A. Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem 2005;38:1-8.
16. Abrahamson M, Dalboge H, Olafsson I, Carlsen S, Grubb A. Efficient production of native, biologically active human cystatin C by Escherichia coli. FEBS Lett 1988;236:14-8.
17. Warfel AH, Zucker-Franklin D, Frangione B, Ghiso J. Constitutive secretion of cystatin C (gammatrace) by monocytes and macrophages and its downregulation after stimulation. J Exp Med 1987;166:1912-7.
18. De Vos J, Thykjaer T, Tarte K, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene 2002;21:6848-57.
19. Choi SJ, Reddy SV, Devlin RD, Menaa C, Chung H, Boyce BF, Roodman GD. Identification of human asparaginyl endopeptidase (legumain) as an inhibitor of osteoclast formation and bone resorption. J Biol Chem 1999;274:27747-53.
20. Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012;307:1941-51.
21. Matsushita K, Tonelli M, Lloyd A, Levey AS, Coresh J, Hemmelgarn BR. Clinical risk implications of the CKD Epidemiology Collaboration (CKD-EPI) equation compared with the Modification of Diet in Renal Disease (MDRD) Study equation for estimated GFR. Am J Kidney Dis 2012;60:241-9.
22. Grubb A, Blirup-Jensen S, Lindstrom V, Schmidt C, Althaus H, Zegers I. First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clin Chem Lab Med 2010;48:1619-21.
23. Blirup-Jensen S, Grubb A, Lindstrom V, Schmidt C, Althaus H. Standardization of cystatin C: development of primary and secondary reference preparations. Scand J Clin Lab Invest Suppl 2008;241:67-70.
24. Manetti L, Pardini E, Genovesi M, et al. Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest 2005;28:346-9.
25. Risch L, Herklotz R, Blumberg A, Huber AR. Effects of glucocorticoid immunosuppression on serum Cystatin C concentrations in renal transplant patients. Clin Chem 2001;47:2055-9.
26. Wasén E, Isoaho R, Mattila K, Vahlberg T, Kivelä SL, Irjala K. Serum cystatin C in the aged: relationships with health status. Am J Kidney Dis 2003;42:36-43.